Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.

Results From Post-Hoc Analyses of the CIBIS II Trial: Effect of Bisoprolol in High-Risk Patient Groups with Chronic Heart Failure

Erland, Erdmann, Philippe, Lechat, Patricia, Verkenne, Hermann, Wiemann · 2001 · European Journal of Heart Failure

Abstract

Background: The beneficial effects of the β-blocker bisoprolol on mortality and rate of hospitalisation as well as its safety in patients with chronic heart failure has been proven. However, its efficacy in patients in whom β-blockers have traditionally been contraindicated or caution has been advised has not been clearly determined. Therefore, analyses in high-risk subgroups of patients taking part in CIBIS II have been performed to investigate the effect of bisoprolol in elderly patients, in patients with type 2 diabetes, with renal failure, NYHA functional class IV or concomitantly treated with digitalis, aldosterone antagonists or amiodarone. Methods: High-risk subgroups of patients with chronic heart failure taking part in the CIBIS II study were retrospectively analysed with respect to mortality, hospitalisation, combined endpoint of cardiovascular mortality or hospitalisation for cardiovascular reasons and treatment withdrawal as well as cause of death and hospitalisation. Analysis is based on intention-to-treat. Results: It was demonstrated that in spite of the expected increase in the overall risk of death and hospitalisation, patients who are diabetic, have renal impairment, NYHA class IV symptoms, are elderly, are taking either digitalis, amiodarone or aldosterone antagonists as co-medication benefit equally from β-blockade with bisoprolol as patients without these complications or drugs. Benefit was shown for the primary endpoint all cause mortality, as well as for the secondary endpoints. Conclusions: Contrary to the hitherto prevailing doctrine of not using beta-blockers in high risk patient groups with chronic heart failure, retrospective analyses of the CIBIS II study justify the use of this drug class in patients regardless of age, NYHA functional class, the presence of diabetes, renal impairment or concomitant treatment with digitalis, amiodarone or aldosterone antagonists.

Overview

Integrity signals

Registry

Crossref · 10.1016/s1388-9842(01)00174-x

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 26 references

Research works printed but not linked: 3

  1. Eichorn, 1999, Practical guidelines for initiation of beta-adrenergic blockade in patients with chronic heart failure, Am J Cardiol, 83, 1A
  2. Packer, 1999, on behalf of the Steering Committee and Membership of the Advisory Council to Improve Outcomes Nationwide in Heart Failure. Consensus Recommendations for the Management of Chronic Heart Failure, II. Management of heart failure: approaches to the prevention of heart failure, Am J Cardiol, 83, 9A
  3. Gottlieb, 1998, Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction, New Engl J Med, 339, 489, 10.1056/NEJM199808203390801 · DOI · Paper page

Cited by

See all 190

Metadata

Authors
Erland, E., Philippe, L., Patricia, V., & Hermann, W.
Affiliations
  • University of Cologne , Joseph-Stelzmann-Str. 9, 50924, Cologne ,
  • Hôpital Pitié Salpétrière , 47, Boulevard de l'Hôpital, F-75651, Paris Cedex 13 ,
  • Merck KGaA , Frankfurter Str. 250, D-64271, Darmstradt ,
Venue
European Journal of Heart Failure
Published
2001-08-01
Volume
3
Issue
4
Pages
469-479
ISSN
  • 1388-9842 (ISSN-L)
  • 1879-0844
OpenAlex
W1987016701
Cited by
190
References
26
Citations by year
2026: 4 · 2025: 4 · 2024: 8 · 2023: 4 · 2022: 7 · 2021: 7 · 2020: 6 · 2019: 6 · 2018: 3 · 2017: 2 · 2016: 3 · 2015: 8 · 2014: 6 · 2013: 3 · 2012: 9
FWCI
6.57
Type
journal article
Language
en
Open access
closed
Locations
  • European Journal of Heart Failure (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
Keywords
bisoprolol, chronic heart failure, beta-blockers, high-risk patient subgroups, type 2 diabetes, renal dysfunction, elderly patients, NYHA functional class IV, digitalis, amiodarone, mineralocorticoid receptor antagonists, all-cause mortality, hospitalization, treatment withdrawal
MeSH terms
Adrenergic beta-Antagonists, Aged, Aged, 80 and over, Cause of Death, Chronic Disease, Diabetes Mellitus, Type 2, Female, Germany, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Probability, Reference Values, Retrospective Studies, Risk Factors, Severity of Illness Index, Confidence Intervals, Survival Analysis, Treatment Outcome, Bisoprolol, Age Distribution, Sex Distribution, Risk Assessment, Renal Insufficiency

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Results From Post-Hoc Analyses of the CIBIS II Trial: Effect of Bisoprolol in High-Risk Patient Groups with Chronic Heart Failure. https://app.cochat.ai/papers/10.1016/s1388-9842(01)00174-x
The paper
Erland, E., Philippe, L., Patricia, V., & Hermann, W. (2001). Results From Post-Hoc Analyses of the CIBIS II Trial: Effect of Bisoprolol in High-Risk Patient Groups with Chronic Heart Failure. European Journal of Heart Failure. https://doi.org/10.1016/s1388-9842(01)00174-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.